


### Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

#### Listing of Claims

Claim 1-3 (cancelled)

4. (currently amended) ~~The method according to claim 1~~ A method of treatment of  
i) HIV-1 infections in mammals, including humans; or  
ii) HBV infections in mammals, including humans;  
which method comprises the administration to the human in need of such treatment, an effective  
amount of the (R)-enantiomer of the triphosphate of a compound of formula (A):



(A)

((R)-PCT-TP), or a pharmaceutically acceptable salt thereof;

wherein the (R)-PCV-TP is in the form of a bioprecursor which is a PL-ASOR derivative, phospholipids derivative, (R)-MP Bis(POM) derivative, (R)-MPT diphenyl ester derivative, or dimyristoylglycerol diphosphate derivative of (R)-PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

5-15 (cancelled)

16. (previously presented) The method according to Claim 4 wherein the bioprecursor is a PL-ASOR derivative.

17. (previously presented) The method according to Claim 4 wherein the bioprecursor is a phospholipids derivative.

18. (previously presented) The method according to Claim 4 wherein the bioprecursor is a (R)-MP Bis(POM) derivative.

19. (previously presented) The method according to Claim 4 wherein the bioprecursor is a (R)-MP diphenyl ester derivative.

20. (previously presented) The method according to Claim 4 wherein the bioprecursor is a dimyristoylglycerol diphosphate derivative